Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dovitinib + androgen deprivation therapy
- Development stage
- Discontinued
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral, Intramuscular, Subcutaneous
01
Overview
Dovitinib + androgen deprivation therapy is a combination treatment investigated for the management of metastatic hormone-sensitive prostate cancer (mHSPC). Dovitinib is an oral, small molecule pan-receptor tyrosine kinase inhibitor that targets several key pathways involved in tumor growth and angiogenesis, including the vascular endothelial growth factor receptors (VEGFR 1-3), fibroblast growth factor receptors (FGFR 1-3), platelet-derived growth factor receptor beta (PDGFRB), and the mast/stem cell growth factor receptor (KIT). In this specific therapeutic context, dovitinib is combined with standard androgen deprivation therapy (ADT)—which typically consists of LHRH agonists, antagonists, or surgical orchiectomy—to evaluate whether dual inhibition of androgen-dependent signaling and alternative growth factor pathways can prolong the time to castration resistance. This combination was notably evaluated in a Phase II clinical trial (NCT01749579) led by Dr. Oscar Goodman, Jr.
- Other names
- Dovitinib lactateDovitinib + ADT
02
Targets
FGFR4 (Fibroblast growth factor receptor 4)VEGFR2 (Vascular endothelial growth factor receptor 2)PDGFRB (Platelet-derived growth factor receptor beta)FGFR3 (Fibroblast growth factor receptor 3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR3 (Vascular endothelial growth factor receptor 3)FGFR2 (Keratinocyte growth factor receptor)FGFR1 (Fibroblast growth factor receptor 1)AR (Adrenergic receptors)
Beyond the preview
Go deeper on Dovitinib + androgen deprivation therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dovitinib + androgen deprivation therapy.